乳腺癌病人可能有隐蔽性甲状腺功能不全

Breast Cancer Patients May Have Subtle Thyroid Dysfunction
乳腺癌病人可能有隐蔽性甲状腺功能不全
October 19, 2007 — Breast cancer patients may have subtle hypothyroidism, even in the absence of overt or subclinical hypothyroidism, a new study suggests. The results were reported at the American Thyroid Association 78th Annual Meeting, in New York, by Peter Smyth, PhD, and colleagues, from University College, Dublin, Ireland.
2007年10月19日－一项新的研究显示，乳腺癌病人可能有隐蔽性甲状腺功能不全，甚至不存在显著或亚临床型甲状腺机能减退症。该结果由爱尔兰都柏林大学的Peter Smyth博士和他的同事在纽约举行的第78届美国甲状腺协会年会上进行报道。
The study compared 710 consecutive patients with postmenopausal breast cancer who were asymptomatic for thyroid disease with 179 postmenopausal controls. The results show that the breast cancer patients had significantly higher levels of antithyroid autoantibodies (TPOAb) and higher levels of serum thyroid stimulating hormone (TSH).
该研究对710名连续性无甲状腺症状的绝经后乳腺癌病人和179名绝经后妇女对照组进行比较。结果显示：乳腺癌病人有显著地更高的抗甲状腺过氧化物酶抗体（TPOAb）水平和更高水平的血清促甲状腺激素（TSH）。
The autoantibodies levels were undetectable in 51.8% of breast cancer patients compared with 82.1% of controls (P < .001), and this relationship continued for detectable values (24.5% in patients vs 3.9% in controls; P < .001) and for elevated values (22.9% in patients vs 14.0% in controls; P < .01).
与对照组的82.1％相比较，自身抗体滴度在51.8％的乳腺癌病人中没有检测到（P < .001），而且这一关联继续用于可检测到滴度病人的数值（病人组24.5% vs对照组 3.9%; P < .001）和滴度升高病人的数值（病人组22.9% vs 对照组14.0%; P < .01）。
Investigation of serum TSH levels in these groups showed not only that there was an association between elevated levels of antithyroid autoantibodies and serum TSH but also that that this association applied to those patients with breast cancer who had detectable levels, Dr. Smyth told the meeting. In the case of elevated levels of antithyroid autoantibodies, serum TSH greater than 4.0 mU/L was found in 61.5% of breast cancer patients compared with 20% of controls (P < .001), while the corresponding figures for detectable levels were 24.3% for patients and 0 for controls (P < .001).
Smyth博士在会议上表示，在这些组中进行的血清TSH水平研究显示：不仅抗甲状腺过氧化物酶抗体滴度升高和血清TSH之间有关联，而且这一关联也适用于这些具有可检测到水平的乳腺癌病人。对于抗甲状腺自身抗体升高水平来说，与对照组中的20％相比较，61.5％的乳腺癌病人的血清TSH 高于4.0 mU/L（P < .001），而对于可检测水平的相应数值来说，病人组为24.3%而对照组为0（P < .001）。
Asked by Medscape Oncology to comment on this finding, Jayne Franklyn, MD, PhD, from Queen Elizabeth Hospital, in Birmingham, United Kingdom, who was not involved with the study, said: \"There has been a suspicion for many years that there is an association between hypothyroidism and breast cancer, but the evidence has been conflicting. What this study shows is that antithyroid antibodies are more likely to be present and more likely to be elevated in breast cancer patients than controls, and these autoantibodies are associated with the very early stages of hypothyroidism.\" It suggests that there may a link between an autoimmune disease such as antibody-positive hypothyroidism and the risk of developing breast cancer, so this work advances the understanding of science, Dr. Franklyn said. However, there are no immediate practical or clinical implications from this work, such as, for example, investigating thyroid function in breast cancer patients, she added.
Medscape Oncology请求来自英国伯明翰地区伊莉莎白皇后医院的Jayne Franklyn博士进行评论，他本人没有参与这项研究。他说，“对于甲状腺功能减退和乳腺癌的相关性已经怀疑很多年，但是证据是冲突的；这项研究显示：与对照组相比较，抗甲状腺抗体很可能在乳腺癌病人上存在而且很可能升高，同时这些自身抗体伴随非常早期的甲状腺功能减退”， Franklyn博士说，该研究显示在诸如抗体阳性的甲状腺功能减退等自身免疫性疾病和发生乳腺癌的风险之间可能存在联系，所以这项研究增进了对学科的理解；然而，她补充到，这项研究没有显示直接实用或临床的关联，例如，在乳腺癌病人中调查的甲状腺功能。
78th Annual Meeting of the American Thyroid Association: Abstract 157. Presented October 5, 2007.
第78届美国甲状腺协会年会；摘要157。出版于2007年10月5日。
http://www.medscape.com/viewarticle/564544
编译（708字）：
乳腺癌病人可能有隐蔽性甲状腺功能不全
2007年10月19日－一项新研究显示，乳腺癌病人可能有隐蔽性甲状腺功能不全。该结果由爱尔兰都柏林大学的Peter Smyth博士和他的同事在纽约举行的第78届美国甲状腺协会年会上进行报道。
本研究对710名连续性无甲状腺症状的绝经后乳腺癌病人和179名绝经后妇女对照组进行比较。结果显示：乳腺癌病人有显著地更高的抗甲状腺过氧化物酶抗体（TPOAb）水平和更高水平的血清促甲状腺激素（TSH）。
研究者在会议上表示，在这些组中进行的血清TSH水平研究显示：不仅抗甲状腺过氧化物酶抗体滴度升高和血清TSH之间有关联，而且这一关联也适用于这些具有可检测到水平的乳腺癌病人。
来自英国伯明翰地区伊莉莎白皇后医院的Jayne Franklyn博士认为，该研究显示在诸如抗体阳性的甲状腺功能减退等自身免疫性疾病和发生乳腺癌的风险之间可能存在联系；但该研究没有显示直接实用或临床的关联。